XIENCE Primary.

Abbott Launches Next-Generation XIENCE PRIME Medication Eluting Stent in International Markets Abbott has announced at the European Society of Cardiology Congress the widespread availability of its next-era XIENCE PRIME Everolimus Eluting Coronary Stent System for the treating coronary artery disease. XIENCE Primary, which received CE Mark in June, offers a novel stent design and a delivery program designed for greater versatility and enhanced deliverability. XIENCE PRIME is currently widely available in European countries and in select countries throughout Latin and Asia-Pacific America canadian levitra . Abbott’s XIENCE PRIME is an improvement in design, deliverability and conformability, all of which could be distinctly observed during coronary stent procedures, in both everyday and complex lesions, said Antonio Bartorelli, M.D., director of the Interventional Cardiology Department of the Centro Cardiologico Monzino, University of Milan, Italy.

Employees are also eligible for President’s Awards, patent/inventor awards and many others. About Abbott As well as the recognition in Technology magazine, Abbott offers been called among the country’s best employers for scientists by The Scientist magazine. The company was recently named among the ‘Best Areas to Launch a Career’ by BusinessWeek magazine and Functioning Mother magazine’s ‘Top 100 Best Companies for Functioning Mothers’ list. Abbott also has been included on DiversityInc magazine’s list of the ‘Top 50 Businesses for Diversity’ for several years. Abbott is a worldwide, broad-based health care company devoted to the discovery, development, advertising and manufacture of pharmaceuticals and medical products, including nutritionals, diagnostics and devices.